Self-controlled Case Series Study for Acute Kidney Injury after Starting Proton Pump Inhibitors or Potassium-Competitive Acid Blocker in Patients with Cancer Using a Large Claims Database

• Published in: Biological & pharmaceutical bulletin 2024/02/23, Vol.47(2), pp.518-526
• Main Authors: Suzuki, Kosuke, Watanabe, Ayako, Kiryu, Yoshihiro, Inoue, Eisuke, Momo, Kenji
• Format: Article
• Language: English
• Subjects: acute kidney injury; Acute Kidney Injury - chemically induced; Acute Kidney Injury - epidemiology; Antineoplastic drugs; Cancer; Databases, Factual; Female; Humans; Incidence; Kidneys; Male; Neoplasms - complications; Neoplasms - drug therapy; Potassium; potassium-competitive acid blocker; proton pump inhibitor; Proton pump inhibitors; Proton Pump Inhibitors - adverse effects; Retrospective Studies; Risk Factors; self-controlled case series study; Sex differences
• ISSN: 0918-6158; 1347-5215
• DOI: 10.1248/bpb.b23-00676

To investigate the risk of acute kidney injury (AKI) in patients with cancer following the initiation of proton pump inhibitors (PPIs) and potassium-competitive acid blocker (PCAB), considering sex and anti-cancer drug use. We conducted a self-controlled case-series study using the Japan Medical Data Center claims data from 12422 patients with cancer who were prescribed PPIs or PCAB between January 2017 and December 2019. Considering the timing of PPI or PCAB, control period (days −120 to −1), risk period 1 (days 0 to +30), and risk period 2 (days +31 to +365) were defined. To assess the incidence rate ratio (IRR) and 95% confidence interval (CI) as the risk ratio, we adjusted for anti-cancer drugs to assess the risk of AKI. Additionally, we also examined sex differences to identify the risk of AKI. AKI was observed in risk period 1 [2.05 (1.12–3.72), p = 0.0192], but a slight reduction was noted in risk period 2 [0.60 (0.36–1.00), p = 0.0481]. A sex-specific increase in the risk of AKI was observed only in males during risk period 1 [2.18 (1.10–4.32), p = 0.0260], with a reduction in risk period 2 [0.48 (0.26–0.89), p = 0.0200]. We identified an increased risk of AKI in patients with cancer starting PPIs or PCAB particularly in males within 30 d after PPI or PCAB initiation, emphasizing the need for vigilant monitoring and management of AKI in this patient population.